Phase 2 Axial Spondy Clinical Trials

7 recruitingPhase 2

What is a Phase 2 trial?

Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.

Showing 17 of 7 trials

Recruiting
Phase 1Phase 2

EAST-1 (ERAP-inhibition in Axial Spondyloarthritis Trial - 1)

Axial Spondyloarthritis (AxSpA)
Grey Wolf Therapeutics141 enrolled15 locationsNCT07047703
Recruiting
Phase 2

A Clinical Study of Tulisokibart (MK-7240) to Treat Radiographic Axial Spondyloarthritis (MK-7240-013)

Radiographic Axial Spondyloarthritis
Merck Sharp & Dohme LLC315 enrolled98 locationsNCT07133633
Recruiting
Phase 2

A Study of SPY072 in Rheumatic Disease

Rheumatoid ArthritisPsoriatic ArthritisRheumatic Diseases+5 more
Spyre Therapeutics, Inc.285 enrolled64 locationsNCT07148414
Recruiting
Phase 2Phase 3

The Investigators Will Evaluate the Diagnostic Performance of [18F]-AlF-FAPI-74 PET/CT in Inflammatory Disorders and Compare it With the Current Gold Standard for Inflammation, FDG PET/CT, in Three Patient Cohort: Patients Presenting With Fever of Unknown Origin, IgG4-RD and AxSpA.

Axial Spondylarthritis (axSpA)IgG4-related DiseaseInflammation of Unknown Origin+1 more
Universitaire Ziekenhuizen KU Leuven140 enrolled1 locationNCT07535554
Recruiting
Phase 2

A Study to Evaluate 608 in Patients With Non- Radiographic Axial Spondyloarthritis (Nr-axSpA)

Axial Spondyloarthritis
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.180 enrolled6 locationsNCT06222671
Recruiting
Phase 2

Fecal Microbiota Transplantation in Axial Spondyloarthritis

Musculoskeletal DiseasesDysbiosisAnkylosing Spondylitis+6 more
University Hospital of North Norway99 enrolled1 locationNCT06451588
Recruiting
Phase 2Phase 3

The Efficacy of Fecal Microbiota Transplatation on Axial Spondyloarthritis Patients Resistant to Conventional Treatment

Axial Spondyloarthritis
Assistance Publique - Hôpitaux de Paris20 enrolled1 locationNCT05654753